Other Titles
Special Session
Abstract
Session presented on Saturday, July 23, 2016:
Children with cancer report treatment-related symptoms as the worst part of treatment that creates difficulties with completing daily activities and are remembered a long time after treatment has ended. They experience multiple symptoms resulting from both disease and treatment. This session will discuss the trajectory of symptom science that established the foundation for exploration of fatigue, sleep, nausea, depression, physical function and motor abilities, as well as memory and cognition changes experienced during childhood cancer treatment. For the past 18 years, this researcher's program has been funded to establish the significance of treatment-related symptoms and their impact on quality of life in children with cancer. During this presentation each of these symptoms will be explored to provide reflection on the experiences of these children. The impact of age, sex, type of cancer and treatment will be reviewed. This body of research has advanced the science by evaluating symptoms and their interactions as well as changes in symptom severity over time, critical aspects that must be incorporated into symptom research. A major revelation from this work critical to understanding symptom experiences during childhood cancer treatment is the need for exploration of 'why' individual symptom differences occur. In the future this will allow us to identify who may be most susceptible to treatment toxicities. Recent research completed by the study team focused on evaluating biological mechanisms that influence the magnitude of symptom toxicity experienced during treatment will be presented. In order to develop effective strategies to reduce symptom toxicity during chemotherapy treatment, a complete understanding of associations need to be identified. Variability of symptom patterns found in this team's numerous studies over the years illustrate the importance in identifying specific factors influencing symptom toxicities. For example, antioxidants and their association with symptoms in children undergoing cancer treatment are discussed during this session to demonstrate the importance of biomarkers and their ability to predict symptom severity during cancer treatment. In the future, as oxidative stress biological markers continue to develop, it will be possible to determine individual susceptibility to oxidative stress and its influence on clinical outcomes and symptom severity.
Sigma Membership
Beta Epsilon
Type
Presentation
Format Type
Text-based Document
Study Design/Type
N/A
Research Approach
N/A
Keywords:
Childhood Cancer Symptom Toxicities, Oxidative Stress, Symptom Trajectories
Recommended Citation
Hockenberry, Marilyn, "Symptom research in children with cancer: One researcher's journey" (2016). INRC (Congress). 248.
https://www.sigmarepository.org/inrc/2016/presentations_2016/248
Conference Name
27th International Nursing Research Congress
Conference Host
Sigma Theta Tau International
Conference Location
Cape Town, South Africa
Conference Year
2016
Rights Holder
All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.
All permission requests should be directed accordingly and not to the Sigma Repository.
All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.
Acquisition
Proxy-submission
Symptom research in children with cancer: One researcher's journey
Cape Town, South Africa
Session presented on Saturday, July 23, 2016:
Children with cancer report treatment-related symptoms as the worst part of treatment that creates difficulties with completing daily activities and are remembered a long time after treatment has ended. They experience multiple symptoms resulting from both disease and treatment. This session will discuss the trajectory of symptom science that established the foundation for exploration of fatigue, sleep, nausea, depression, physical function and motor abilities, as well as memory and cognition changes experienced during childhood cancer treatment. For the past 18 years, this researcher's program has been funded to establish the significance of treatment-related symptoms and their impact on quality of life in children with cancer. During this presentation each of these symptoms will be explored to provide reflection on the experiences of these children. The impact of age, sex, type of cancer and treatment will be reviewed. This body of research has advanced the science by evaluating symptoms and their interactions as well as changes in symptom severity over time, critical aspects that must be incorporated into symptom research. A major revelation from this work critical to understanding symptom experiences during childhood cancer treatment is the need for exploration of 'why' individual symptom differences occur. In the future this will allow us to identify who may be most susceptible to treatment toxicities. Recent research completed by the study team focused on evaluating biological mechanisms that influence the magnitude of symptom toxicity experienced during treatment will be presented. In order to develop effective strategies to reduce symptom toxicity during chemotherapy treatment, a complete understanding of associations need to be identified. Variability of symptom patterns found in this team's numerous studies over the years illustrate the importance in identifying specific factors influencing symptom toxicities. For example, antioxidants and their association with symptoms in children undergoing cancer treatment are discussed during this session to demonstrate the importance of biomarkers and their ability to predict symptom severity during cancer treatment. In the future, as oxidative stress biological markers continue to develop, it will be possible to determine individual susceptibility to oxidative stress and its influence on clinical outcomes and symptom severity.